Pharmaceutical Giant Lilly Launches SGD$42 Million Digital Health Innovation Hub in Singapore
Eli Lilly and Company’s digital health arm, Lilly Digital Health, in partnership with the Lilly Centre for Clinical Pharmacology (LCCP), has unveiled plans to establish a cutting-edge digital health innovation hub in Singapore with an investment of SGD$42 million. The initiative is part of a strategic five-year roadmap supported by the Singapore Economic Development Board (EDB) to advance the research and development of AI-powered digital health technologies.
The Magnol.AI Platform
The innovation hub will be equipped with Lilly’s proprietary Magnol.AI platform, designed to enable the secure ingestion, visualization, and processing of high-frequency sensor data gathered from wearable devices. By integrating clinician and patient-reported outcomes, Magnol.AI enables real-time data analysis capabilities, empowering clinical scientists to conduct high-quality digital health research with enhanced accuracy and efficiency.
Strategic Partnership with Singapore EDB
Goh Wan Yee, Senior Vice President and Head of Healthcare at Singapore EDB, expressed enthusiasm over Eli Lilly’s decision to establish the Digital Health Innovation Hub in Singapore. This strategic collaboration aligns with Singapore’s vision to leverage AI-driven technologies for accelerated global clinical development, in line with the National AI Strategy 2.0.
Advancements in Clinical Trials
As part of the innovation hub, Lilly will introduce a state-of-the-art smart toilet equipped with pressure sensors to monitor the duration and frequency of participants’ bathroom usage during clinical trials. This innovative approach eliminates the need for manual data logging, offering researchers valuable insights into the impact of medications under investigation.
Collaborative Ventures in Healthcare
Eli Lilly’s recent partnership with Genetic Leap to develop genetic medicine therapeutics and collaborations with diabetes management companies signify the company’s commitment to driving innovation in healthcare. Through strategic alliances and technology integrations, Lilly continues to enhance its product offerings and digital health capabilities.
Industry Trends and Innovations
Eli Lilly joins a cohort of pharmaceutical companies, including Pfizer, Novartis, Roche, AstraZeneca, and Johnson & Johnson, in establishing digital health innovation hubs to pioneer advancements in healthcare delivery and patient outcomes. These initiatives underscore the industry’s collective efforts to harness technology for improved clinical research and personalized patient care.
